Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026
Same author

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026
Same author

Mogamulizumab as Bridge to Thiotepa-Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single-Centre Experience.

EJHaem·2026
Same author

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

HemaSphere·2026
Same author

Humoral and Cellular Immune Response in Patients with Hematological Disorders After Three Doses of mRNA COVID-19 Vaccine: A Single-Center Observational Study.

Vaccines·2026

Related Experiment Video

Updated: Jul 5, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K

Curative intent therapy for DLBCL in the elderly.

Alessandra Tucci1, Lorenzo Masina1, Stefano Luminari2

  • 1Hematology Unit, ASST Spedali Civili, Brescia, Italy.

Leukemia & Lymphoma
|January 11, 2024
PubMed
Summary
This summary is machine-generated.

Geriatric assessment stratifies older adults with aggressive lymphoma into fit, unfit, and frail groups. Tailored treatments, including novel agents, improve outcomes for these heterogeneous patient populations.

Keywords:
DLBCLgeriatric assessmentolder patients

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.0K

Related Experiment Videos

Last Updated: Jul 5, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.0K

Area of Science:

  • Oncology
  • Geriatrics

Background:

  • Older patients with aggressive lymphoma present significant heterogeneity.
  • Functional limitations, comorbidities, and disease biology impact treatment decisions.

Purpose of the Study:

  • To outline a treatment strategy for older patients with aggressive lymphoma.
  • To highlight the role of geriatric assessment in tailoring therapy.

Main Methods:

  • Stratification of patients into fit, unfit, and frail categories using multidimensional geriatric assessment (GA).
  • Evaluation of treatment approaches based on geriatric category, including R-CHOP, dose-intensity reduction, and novel targeted agents.

Main Results:

  • Fit patients tolerate standard R-CHOP, achieving outcomes similar to younger patients.
  • Unfit patients benefit from dose-intensity reduction to balance toxicity and efficacy.
  • Frail patients may benefit from chemo-free regimens with novel targeted drugs.

Conclusions:

  • Geriatric assessment is crucial for personalizing aggressive lymphoma treatment in older adults.
  • Novel targeted agents are transforming therapeutic options for older patients, including first-line and relapsed/refractory settings.